Education
About Us
Working with TipRanks
Follow Us
InMed Pharmaceuticals (INM)
NASDAQ:INM
Total Valuation
InMed Pharmaceuticals has a market cap or net worth of $5.29M. The enterprise value is -$4.26B.
Market Cap$5.29M
Enterprise Value-$4.26B
Share Statistics
InMed Pharmaceuticals has 2,002,186 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,002,186
Owned by Insiders19.32%
Owned by Institutions<0.01%
Financial Efficiency
InMed Pharmaceuticals’s return on equity (ROE) is -0.83 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-0.83
Return on Assets (ROA)-0.65
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee483.69K
Profits Per Employee-590.43K
Employee Count13
Asset Turnover0.39
Inventory Turnover2.81
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value4.16
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio<0.01
Income Statement
In the last 12 months, InMed Pharmaceuticals had revenue of 6.29M and earned -10.50M in profits. Earnings per share was -10.07.
Revenue6.29M
Gross Profit1.51M
Operating Income-11.12M
Pretax Income-10.49M
Net Income-10.50M
EBITDA-10.30M
Earnings Per Share (EPS)-10.07
Cash Flow
In the last 12 months, operating cash flow was -7.81B and capital expenditures 0.00, giving a free cash flow of -7.81B billion.
Operating Cash Flow-7.81B
Free Cash Flow-7.81B
Free Cash Flow per Share-3.90K
Dividends & Yields
InMed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.73
52-Week Price Change-51.11%
50-Day Moving Average2.86
200-Day Moving Average3.57
Relative Strength Index (RSI)45.20
Average Volume (3m)3.86M
Important Dates
InMed Pharmaceuticals upcoming earnings date is Sep 19, 2025, Before Open (Confirmed).
Last Earnings DateMay 12, 2025
Next Earnings DateSep 19, 2025
Ex-Dividend Date―
Financial Position
InMed Pharmaceuticals as a current ratio of 4.41, with Debt / Equity ratio of 5.97%
Current Ratio4.41
Quick Ratio3.78
Debt to Market Cap0.00
Net Debt to EBITDA0.79
Interest Coverage Ratio0.00
Taxes
In the past 12 months, InMed Pharmaceuticals has paid 9.71K in taxes.
Income Tax9.71K
Effective Tax Rate>-0.01
Enterprise Valuation
InMed Pharmaceuticals EV to EBITDA ratio is -4.63, with an EV/FCF ratio of -4.68.
EV to Sales7.12
EV to EBITDA-4.63
EV to Free Cash Flow-4.68
EV to Operating Cash Flow-4.68
Balance Sheet
InMed Pharmaceuticals has $4.72B in cash and marketable securities with $419.35M in debt, giving a net cash position of -$4.30B billion.
Cash & Marketable Securities$4.72B
Total Debt$419.35M
Net Cash-$4.30B
Net Cash Per Share-$2.15K
Tangible Book Value Per Share$0.97
Margins
Gross margin is -267.35%, with operating margin of 0.00%, and net profit margin of -166.94%.
Gross Margin-267.35%
Operating Margin0.00%
Pretax Margin-166.79%
Net Profit Margin-166.94%
EBITDA Margin-153.64%
EBIT Margin-176.92%
Analyst Forecast
The average price target for InMed Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-12.53%
EPS Growth Forecast48.59%